文献速递主动脉外科瓣膜外科

保留瓣膜的主动脉根部置换术(David I 手术)在马方病中的应用:单中心20余年逾100例经验

Valve-sparing aortic root replacement (David I procedure) in Marfan disease: single-centre 20-year experience in more than 100 patients†.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该单中心回顾性研究分析了1993至2015年间104例马方病患者接受David I再植入式保留瓣膜主动脉根部置换术的长期结局,平均随访12±5.4年。马方病患者10年生存率91%、20年76%,免于主动脉瓣再手术率10年86%、20年80%,再手术率与非马方病患者相似(P=0.60)。作者认为该术式在马方病患者中远期结局良好,修复耐久性受围手术期形态学因素影响,建议专门培训。

要点

  • 马方病患者David I术后10年生存率91%、20年76%,显著优于非马方病患者(P<0.0001)。
  • 马方病患者免于主动脉瓣再手术率10年86%、20年80%,再手术率与非马方病患者相似(P=0.60)。
  • 未处理的瓣叶脱垂、交界成形、瓣叶成形和移植物尺寸不匹配预测长期死亡(P=0.0054)。

核心结论

  • 采用David I再植入技术的保留瓣膜主动脉根部置换术在马方病患者中取得良好的长期结局,遗传疾病不影响远期瓣膜功能,修复耐久性受围手术期形态学标准和手术经验影响,建议专门培训。

研究设计与样本

  • 单中心回顾性研究,1993至2015年间共582例患者在本机构接受保留瓣膜主动脉根部置换术(David I再植入),其中104例为马方病,由13名外科医生实施手术,平均随访12±5.4年(共1201患者年)。

主要发现

  • 马方病患者早期死亡率为0.96%,长期生存率10年为91%、20年为76%。
  • 马方病患者生存率显著优于非马方病患者(P<0.0001)。
  • 马方病患者免于主动脉瓣再手术率10年为86%、20年为80%,再手术率与非马方病患者相似(P=0.60)。
  • 围手术期形态学特征(未处理的脱垂、交界成形、瓣叶成形和移植物尺寸不匹配)预测长期死亡(P=0.0054);移植物尺寸不匹配和未处理的脱垂预测结构性瓣膜退化(两者P<0.0001)。
  • 无事件生存者远期瓣膜功能良好:平均跨瓣压差4.2(2.9-6.9)mmHg,98%主动脉瓣反流≤轻度;无瓣膜相关血栓栓塞或出血事件,心内膜炎发生率为0.96%,随访期间仅17%患者口服抗凝药。

临床怎么用

  • 作者认为,采用David I再植入技术的保留瓣膜主动脉根部置换术在马方病患者中可获得良好的长期结局,修复耐久性受围手术期形态学标准和手术经验影响,建议专门培训。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Valve-sparing aortic root replacement (VSARR) is recommended for patients with aortic root dilatation and preserved aortic valve cusp morphology. The durability of VSARR in Marfan patients has been questioned. The aim of our study was to establish the long-term outcomes of VSARR in Marfan patients. METHODS: Between 1993 and 2015, 582 patients underwent VSARR (David I reimplantation) at our institution. Of these patients, 104 had Marfan disease. Thirteen surgeons performed the procedures in this group. The mean follow-up time was 12 ± 5.4 years (1201 patient-years). RESULTS: Early mortality was 0.96%, and long-term survival was 91% at 10 years and 76% at 20 years in Marfan patients. Marfan patients had a significantly better survival compared to non-Marfan patients (P < 0.0001). Freedom from aortic-valve reoperation was 86% at 10 years and 80% at 20 years in Marfan patients. The reoperation rate was similar in Marfan and non-Marfan patients (P = 0.60). Morphological perioperative features (untreated prolapse, commissural plasty, cusp plasty and graft size mismatch) predicted long-term mortality (P = 0.0054). Graft size mismatch and untreated prolapse predicted structural valve deterioration (both P < 0.0001). Long-term valve function in event-free survivors was excellent [mean gradient 4.2 (2.9-6.9), 98% aortic regurgitation ≤ mild]. There were no valve-related thromboembolic or bleeding events. The endocarditis rate was 0.96%. Only 17% of the patients were on oral anticoagulants during the follow-up. CONCLUSIONS: VSARR using the David I reimplantation technique results in excellent long-term outcomes in Marfan patients. We present the longest follow-up period so far. The genetic disease does not affect long-term valve function. The durability of the repair is affected by morphological perioperative criteria depending on surgical expertise, and dedicated training is recommended.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Martens A, Beckmann E, Kaufeld T, et al. Valve-sparing aortic root replacement (David I procedure) in Marfan disease: single-centre 20-year experience in more than 100 patients†. Eur J Cardiothorac Surg. 2019. PMID: 30169770. doi:10.1093/ejcts/ezy300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。